头颈癌患者强化临床与影像学随访监测研究
本研究回顾性分析1998至2010年间接受放化疗的326例III-IV期头颈癌患者,采用强化临床与影像学随访方案。结果显示随访发现106例复发(32%),其中约70%通过临床和/或影像学发现,30%因症状诊断;可治愈复发的中位总生存期在两种检测方式间无显著差异。结论认为强化随访发现更多复发但可治愈性相似,需前瞻性试验确定最佳随访策略。
要点
- 强化临床与影像学随访可发现更多复发/第二原发癌,但可治愈性与症状驱动监测相似。
- 复发中位总生存期在临床/影像学发现与症状发现间无显著差异(89个月 vs 85个月)。
- 需前瞻性试验确定头颈癌最有效随访策略。
核心结论
- 临床与影像学随访比症状驱动监测发现更多复发/第二原发癌,但复发可治愈性在检测方式间相似。
研究设计与样本
- 回顾性分析,单中心学术三级医疗中心,纳入1998至2010年间接受放化疗的III-IV期头颈癌患者326例。
主要发现
- 共检测到106例复发(32%),其中38例(36%)为局部区域复发,44例(41%)为远处转移,24例(23%)为第二原发癌。
- 约70%复发通过临床和/或影像学发现,30%因患者症状诊断。
- 临床和/或影像学发现的74例复发/第二原发癌中26例(35%)接受治愈性治疗,症状诊断的32例中9例(28%)接受治愈性治疗。
- 可治愈复发病例的中位总生存期在临床/影像学检查与症状诊断间无显著差异(89个月 vs 85个月)。
临床怎么用
- 强化临床与影像学随访可增加复发检出,但未显著改善可治愈复发的中位总生存期,临床决策需权衡随访强度与获益。
局限性
- 回顾性研究设计,单中心数据,需前瞻性试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: There is no consensus on the follow-up modalities in patients with head and neck cancer. This study aims to describe the pattern and survival outcomes of recurrences/second primary cancers in patients undergoing an intensive radiologic and clinical follow-up. STUDY DESIGN: Retrospective analysis. SETTING: Single academic tertiary care center. SUBJECTS AND METHODS: All patients with stage III-IV head and neck cancer treated with chemoradiotherapy at our institution between 1998 and 2010 were retrospectively reviewed. Persistent/recurrent disease within 6 months since the curative treatment and second primary cancers outside the upper aerodigestive tract were excluded. Data were analyzed by descriptive statistics. Surveillance was planned every 3 months in the first year, then with increasing intervals till the fifth year. RESULTS: A total of 326 patients were included. Out of all detected cancer recurrences (n = 106, 32%), 38 (36%) were locoregional, 44 (41%) were distant, and 24 (23%) were second primary cancers. Approximately 70% of recurrences were clinically and/or radiologically discovered, while 30% were diagnosed due to the patients' symptoms. Of all clinically and/or radiologically discovered recurrences/second primary cancers (n = 74), 26 (35%) were curatively treated, with respect to 9 of the 32 (28%) diagnosed by symptoms. Median overall survival of recurrent curable cases did not significantly differ according to the detection modality (89 months by clinical/radiologic examination vs 85 by symptoms). CONCLUSIONS: Clinical and radiologic follow-up identified more recurrences/second primary cancers than the symptom-driven monitoring, but the curability of cancer recurrence was similar regardless of detection modality. Prospective trials are needed to define the most effective follow-up strategy in head and neck cancer.
引用
- Imbimbo M, Alfieri S, Botta L, et al. Surveillance of Patients with Head and Neck Cancer with an Intensive Clinical and Radiologic Follow-up. Otolaryngol Head Neck Surg. 2019. PMID: 31286827. doi:10.1177/0194599819860808
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。